Wedbush analyst Liana Moussatos reiterated a Buy rating on Miragen Therapeutics (MGEN) today and set a price target of $6.00. The company’s shares closed last Tuesday at $1.22.
According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 14.5% and a 55.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Miragen Therapeutics with a $5.33 average price target.
See today’s analyst top recommended stocks >>
Based on Miragen Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $828K and GAAP net loss of $8.04 million. In comparison, last year the company earned revenue of $372K and had a GAAP net loss of $11.63 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
Read More on MGEN:
